Mackenzie Financial
SUPN icon

Mackenzie Financial’s Supernus Pharmaceuticals SUPN Stock Holding History

Mackenzie Financial’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4,480
Closed -$223K – 1739
2025
Q4 		$223K Buy
+4,480
New +$218K ﹤0.01% 1500

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mackenzie Financial's SUPN Position: Q1 2026 in Review

Mackenzie Financial sold out of Supernus Pharmaceuticals (SUPN) in Q1 2026, closing a stake of 4,480 shares — an estimated $223K sold.

Mackenzie Financial first reported a position in SUPN in Q4 2025 and held it in 1 quarter. The position peaked at $223K in Q4 2025. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • Mackenzie Financial reported no remaining Supernus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Mackenzie Financial sold 4,480 Supernus Pharmaceuticals shares in Q1 2026, an estimated $223K.
  • Mackenzie Financial first reported a position in Supernus Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Mackenzie Financial's Supernus Pharmaceuticals position peaked at $223K in Q4 2025.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Mackenzie Financial's 13F filing for Q1 2026, filed 13 May 2026.